Real-life prospective study on tocilizumab in severe COVID-19 infection
L. Power (Dublin, Ireland), B. Morarasu (Dublin, Ireland), A. Sarfaraz (Dublin, Ireland), A. Basirat (Dublin, Ireland), H. Rahman (Dublin, Ireland), S. Donnelly (Dublin, Ireland), E. Moloney (Dublin, Ireland), M. Kooblall (Dublin, Ireland), S. Lane (Dublin, Ireland)
Source: International Congress 2022 – COVID treatments
Session: COVID treatments
Session type: Thematic Poster
Number: 2606
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Power (Dublin, Ireland), B. Morarasu (Dublin, Ireland), A. Sarfaraz (Dublin, Ireland), A. Basirat (Dublin, Ireland), H. Rahman (Dublin, Ireland), S. Donnelly (Dublin, Ireland), E. Moloney (Dublin, Ireland), M. Kooblall (Dublin, Ireland), S. Lane (Dublin, Ireland). Real-life prospective study on tocilizumab in severe COVID-19 infection. 2606
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|